Although treating BRAF-mutant melanoma with BRAF and MEK inhibition has shown effectiveness despite notable treatment-related side effects, the scrutiny of drug-drug interactions impacting the toxicity linked to anti-BRAF/anti-MEK therapy has become imperative. The gene discussed is BRAF; the disease is melanoma.